Global Tax Intern
Alexion Pharmaceuticals, Inc.
Summary
Alexion-AstraZeneca Rare Disease is seeking undergraduate rising Juniors and Seniors majoring in Tax, Accounting, or a related field for a 10-week internship role at our site in New Haven, CT from June 07, 2027 to August 13, 2027.
Job description
Tax Planning & Administration
- Conduct basic US federal and state tax research as requested using RIA Checkpoint on issues impacting the company
- Provide support on corporate tax projects and initiatives
- Assist with drafting tax transactions related to legal documents
- Documenting the changes to the tax structure as a result of acquisitions and other transactions
- Complete special projects as assigned
Tax Compliance
- Assist in the coordination of the data gathering of the information needed to prepare the Company's tax returns
- Engage with Global Tax Master Service Provider on various aspects of global tax compliance
- Support in gathering information and supporting State income and franchise tax audits
- Assist with arranging information and drafting documentation for Transfer Pricing reports
Requirements
- Rising Junior and Rising Senior students majoring in Tax, Accounting, or a related field
- Strong computer skills and functionality with the Microsoft Office 365 suite of products
- Attention to detail and accuracy, with an ability to handle multiple assignments and to work independently for periods of time
- Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
- Candidates must have an expected graduation date after August 2027
- US Work Authorization is required at time of application
- This role will not be granting CPT support
- Ability to report onsite to New Haven, CT site 3-5 days per week
- This role will not provide relocation assistance
Company overview
Alexion Pharmaceuticals, Inc., now a subsidiary of AstraZeneca, is a leading pharmaceutical company specializing in the development and commercialization of orphan drugs for rare diseases. Founded in 1992 and headquartered in Boston, Massachusetts, the company has established itself as a pioneer in treating ultra-rare disorders through innovative biologic therapies. Alexion's flagship products include Soliris (eculizumab) and Ultomiris (ravulizumab), both used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company's portfolio also features Strensiq (asfotase alfa) for hypophosphatasia, Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency, and Andexxa (andexanet alfa) for reversing anticoagulation effects. With approximately 2,525 employees and annual revenues exceeding $6 billion, Alexion operates globally, focusing on life-transforming treatments for patients with severe and life-threatening rare diseases. The company's acquisition by AstraZeneca in 2021 has further strengthened its position in the rare disease therapeutic area, combining Alexion's specialized expertise with AstraZeneca's global reach and research capabilities.